BP1.4979
BP1.4979 is a selective dopamine D 3 receptor agonist which is under development for the treatment of binge-eating disorder, obsessive–compulsive disorder (OCD), restless legs syndrome (RLS), and smoking withdrawal.
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BP1.4979 is a selective dopamine D 3 receptor agonist which is under development for the treatment of binge-eating disorder, obsessive–compulsive disorder (OCD), restless legs syndrome (RLS), and smoking withdrawal. It is taken orally. The drug acts as a highly potent weak partial agonist of the dopamine D 3 receptor (K i = ~1 nM; = 0.7 nM; = 32%).
It has around 200-fold higher affinity for the dopamine D 3 receptor than for the dopamine D 2 receptor (K i = 192 nM), where it is an antagonist. BP1.4979 showed 66% dopamine D 3 receptor occupancy and 8% dopamine D 2 receptor occupancy with positron emission tomography (PET) imaging in a clinical study.
The time to peak levels of BP1.4979 is 1 hour and its elimination half-life is about 8 hours. The drug is under development by Bioprojet. As of January 2026, it is in phase 2 clinical trials for all indications.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372016782 under CC BY-SA 4.0; modifications have been made.